| 56 |
Cited non-patent literature identified in the search |
CTNP |
ALEXANDER MAIWALD ET AL: "Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 31, no. sup1, 11 May 2016 (2016-05-11), GB, pages 89 - 97, XP055748134, ISSN: 1475-6366, DOI: 10.3109/14756366.2016.1172574 0;
COLOMBO ELOÏC ET AL: "Design and synthesis of potent, selective inhibitors of matriptase", ACS MEDICINAL CHEMISTRY LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 3, no. 7, 12 July 2012 (2012-07-12), pages 530 - 534, XP008173043, ISSN: 1948-5875, [retrieved on 20120411], DOI: 10.1021/ML3000534 0;
DOMINIC DUCH?NE ET AL: "Analysis of Subpocket Selectivity and Identification of Potent Selective Inhibitors for Matriptase and Matriptase-2", JOURNAL OF MEDICINAL CHEMISTRY, VOL. 57, N.23, 11 November 2014 (2014-11-11), pages 10198 - 10204, XP055429365, Retrieved from the Internet [retrieved on 20171128], DOI: 10.1021/jm5015633 0;
HOFFMANN MARKUS ET AL: "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no. 2, 5 March 2020 (2020-03-05), pages 271, XP086136225, ISSN: 0092-8674, [retrieved on 20200305], DOI: 10.1016/J.CELL.2020.02.052 0;
KWON HONGMOK ET AL: "Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors", BIORGANIC & MEDICINAL CHEMISTRY LETTERS,, vol. 26, no. 2, 8 December 2015 (2015-12-08), pages 310 - 314, XP029380287, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2015.12.023 0;
WILLIAM C RIPKA: "New thrombin inhibitors in cardiovascular disease", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 1, no. 2, 1 August 1997 (1997-08-01), GB, pages 242 - 253, XP055748161, ISSN: 1367-5931, DOI: 10.1016/S1367-5931(97)80016-6 0;
ZHENFU HAN ET AL: "Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer", ACS MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 11, 10 October 2014 (2014-10-10), US, pages 1219 - 1224, XP055748199, ISSN: 1948-5875, DOI: 10.1021/ml500254r 0
|
| 56 |
Cited non-patent literature indicated by the applicant |
CTNP |
ABEL T, BLOOD, vol. 122, 2013, pages 2030 - 2038 1;
DEMAISON C, HUM GENE THER., vol. 13, 2002, pages 803 - 813 1;
HOFFMANN ET AL., CELL, vol. 181, 2020, pages 271 - 280 1;
HURET JLAHMAD MARSABAN MBERNHEIM ACIGNA JDESANGLES FGUIGNARD JCJACQUEMOT-PERBAL MCLABARUSSIAS MLEBERRE V, NUCLEIC ACIDS RES., vol. 41, January 2013 (2013-01-01) 1;
KOUJI SAKAI ET AL., JOURNAL OF VIROLOGY, vol. 88, no. 10, 2014, pages 5608 - 5616 1;
MUNCH RC, MOL THER, vol. 19, 2011, pages 686 - 693 1;
ROMAIN ZUFFEREY, NAT. BIOTECHNOL., vol. 3, 1997, pages 3 - 8 1;
W-J SHIN ET AL., EXPERT OPINION ON DRUG DISCOVERY, vol. 12, no. 11, 2017, pages 1139 - 1152 1;
XIA S: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike", SCI ADV, vol. 5, 2019, pages eaav4580 1
|
